आरती ड्रग्स शेअर किंमत

Pharmaceuticals company Aarti Drugs announced Q4FY26 & FY26 results Q4FY26 Consolidated Financial Highlights: Revenue stood at Rs 721.1 crore as compared to Rs 678.6 crore in Q4FY25 and Rs 602.9 crore in Q3FY26, reflecting a growth of 6% YoY and 20% QoQ respectively EBITDA stood at Rs 96.6 crore versus Rs 95.2 crore in Q4FY25 and Rs 56.3 crore in Q3FY26, flat YoY and a growth of 72% QoQ. EBITDA margin stood at 13.4% PAT stood at Rs 55.3 crore as compared to Rs 62.8 crore in Q4FY25 and Rs 40.5 crore in Q3FY26, a degrowth of 12% YoY and up 36% QoQ. PAT margin translated to 7.7% for Q4FY26 FY26 Consolidated Financial Highlights: Revenue stood at Rs 2,567.7 crore as compared to Rs 2,403.4 crore in FY25, reflecting a growth of 7% YoY EBITDA stood at Rs 311.6 crore versus Rs 303.5 crore in FY25, up 3% YoY, with EBITDA margin at 12.1% PAT stood at Rs 194.9 crore as compared to Rs 168.2 crore in Q4FY25, up 16% YoY, translating to a PAT margin of 7.6% Q4FY26 Standalone Business Highlights: Revenue stood at Rs 631.7 crores vs. Rs 623.0 crores in Q4FY25 Standalone business contributed 88% to the consolidated revenue 63% of the standalone revenue came from the domestic market and 37% from the exports market Domestic revenue grew 7% YoY and export revenue declined by 7% YoY Within the API business, the anti-biotic therapeutic category contributed 37.8%, anti-protozoal 19.6%, anti-inflammatory 11.9%, anti-diabetic 15.0%, antifungal 10.0% and the rest contributed 5.7% to total API sales Business Highlights: Revenue from formulations stood at Rs 91.3 crore compared to Rs 64.8 crore in Q4FY25, up 41% YoY. Exports contributed 69% to this revenue For FY26, formulation revenue was Rs 330.5 crore compared to Rs 284.9 crore in FY25, up 16%, with exports accounting for 65% of total formulation sales Adhish Patil, CFO & COO, Aarti Drugs, said, “FY26 marked an important transition year for Aarti Drugs Limited, as the Company progressed through a major investment and commissioning cycle while navigating a challenging industry environment. Despite persistent macroeconomic headwinds, pricing pressure in select API segments, and elevated raw material volatility, our core business delivered a strong sequential recovery during Q4FY26, supported by operational scale-up of the Sayakha facility, improving export traction and a better product mix. Total revenue for Q4FY26 stood at Rs 721.1 crore, reflecting growth of 6% YoY. EBITDA remained flat YoY to Rs 96.6 crore, with margin at 13.4%, a decline of 60 bps. The year’s profitability remained impacted by two key factors — start-up losses associated with the new facilities, and continued weakness in the domestic antibiotics market. On a sequential basis, however, performance improved sharply, with revenue and EBITDA rising 20% and 72% respectively, and margins expanding by 410 basis points compared to the previous quarter. This was primarily due to the strong execution progress in our Sayakha facility, which achieved a milestone run-rate of ~1,000 tonnes per month in March 2026. While the scale-up trajectory could have been faster, temporary ammonia shortages impacted production. Nevertheless, the project has now entered a more stable operating phase and is expected to progressively enhance margin resilience and backward integration benefits going forward. We are also encouraged by the continued improvement in our business mix. Regulated market contribution increased from 66% in FY25 to 73% in FY26, while exports contribution rose from 35% to 38% over the same period. This shift toward regulated and export-oriented business continues to support margin quality and earnings stability. Diversification initiatives also gained momentum during the year, with the Formulations and Specialty Chemicals segments growing 33% and 37% YoY, respectively. From an industry perspective, FY26 witnessed sustained pressure on API realizations, especially during the first half of the year. However, pricing trends began stabilizing from September 2025 onwards, with the recovery trajectory strengthening further during Q4FY26. At the same time, the sharp increase in key raw material prices and logistics costs — exacerbated by supply chain disruptions arising from geopolitical tensions in West Asia — created additional cost pressures across the industry. Despite these challenges, the Company was able to partially offset cost inflation through calibrated price increases and improved product mix across its core portfolio. The Company’s broad product basket, diversified customer base, and increasing share of regulated market business continue to mitigate concentration risks while improving business resilience. Regulatory filings and approvals across the EU and US markets remain a strategic priority, as these markets offer significant realization and margin upside for several existing products. The foundations built over the last few years — including backward integration, expanded regulatory approvals, formulations capability, and specialty product development — position the Company favourably for a meaningful improvement in profitability and return ratios over FY27 and beyond.” Result PDF

• ट्रेंडलाईन
• 4 दिवस 9 तासांपूर्वी

Q4FY26 आणि पूर्ण वर्षाची कामगिरी आणि दृष्टीकोन यावर आरती ड्रग्स मॅनेजमेंट आणि विश्लेषकांसह कॉन्फरन्स कॉल. पूर्ण कमाईची ट्रान्सक्रिप्ट ऐका.

• ट्रेंडलाईन
• 6 दिवस 12 तासांपूर्वी

Q3FY26 परफॉर्मन्स आणि आऊटलूक वर आरती ड्रग्स मॅनेजमेंट आणि ॲनालिस्टसह कॉन्फरन्स कॉल. पूर्ण कमाईची ट्रान्सक्रिप्ट ऐका.

• ट्रेंडलाईन
• 3 महिने 2 आठवड्यांपूर्वी